Making Immunotherapy Mainstream An immunotherapy procedure showing promise in the treatment of mesothelioma may soon be covered under Medicare. In August, the Centers for Medicare & Medicaid Services (CMS) approved the use of Chimeric Antigen Receptor, (CAR T-cell), therapy in patients with two specific cancers: non-Hodgkin lymphoma and B-cell precursor acute lymphoblastic leukemia. CAR T-cell … Continued
The results of a recent Phase 3 clinical trial have led to a disappointing setback for the mesothelioma community: a highly-touted immunotherapy drug has failed to stop the progression of the disease. Researchers involved in the LUME-Meso study, which combined Ofev (nintedanib) with first-line chemotherapy drugs, say the treatment failed to slow the progression of … Continued
An new Phase 1 clinical trial using chimeric antigen receptor (CAR) T-cell therapy to attack pleural mesothelioma tumors shows promise for cancer patients.
A new type of immunogene therapy, also called virotherapy, is the subject of a Phase 3 clinical trial for patients diagnosed with pleural mesothelioma.